

**Pfizer Inc.**  
275 North Field Drive  
Lake Forest, IL 60045



March 22, 2023

**Notice Regarding Solu-Cortef® (hydrocortisone sodium succinate for injection, USP)  
Availability**

Dear Healthcare Providers, Customers and Patients,

The purpose of this letter is to make you aware of a supply disruption of Pfizer's **Solu-Cortef® (hydrocortisone sodium succinate for injection, USP) 100 mg/2 mL (50 mg/mL) ACT-O-VIAL™ Single Dose Vial** presentations and provide guidance on how to access product reserved for patient specific emergency needs.

Pfizer understands the importance of this product to patients and clinicians and is working as quickly as possible to resolve the production and operational challenges that led to this manufacturing delay. In the interim, we have implemented proactive inventory management measures to ensure available product can reach patients in need.

Pfizer estimates the ability to return to historical production levels in June 2023, with some limited intermittent deliveries occurring prior to June. Pfizer will provide updates on this situation as more information becomes available.

Currently, all Solu-Cortef® (hydrocortisone sodium succinate for injection, USP) inventory is available from Pfizer through direct order only, and Pfizer is allocating limited quantities to institutions with a history of product purchases.

**IMPORTANT, PLEASE NOTE: If you have a specific patient(s) in need of Solu-Cortef® (hydrocortisone sodium succinate for injection, USP) 100 mg/2 mL (50 mg/mL) ACT-O-VIAL™ Single Dose Vial, please utilize Pfizer's emergency request process detailed below.**

- Under Pfizer's emergency request process Pfizer will distribute **Solu-Cortef® (hydrocortisone sodium succinate for injection, USP) 100 mg/2 mL (50 mg/mL) ACT-O-VIAL™ Single Dose Vial**, NDC 00009-0011-03, direct to healthcare providers (HCPs) or pharmacies only in situations in which providers or pharmacies are unable to gain access to product through direct order from Pfizer.
- HCPs or pharmacies can request product under the emergency request process by completing the [Emergency Request Form](#). Completed forms should be emailed to [PISupplyContinuity@pfizer.com](mailto:PISupplyContinuity@pfizer.com). Requests will be reviewed and filled in the order they are received and only with the completed documentation. See the form linked [HERE](#) for additional details.
- **Patients:** Pfizer can only release product to licensed health care providers or pharmacies. If you are in need of **Solu-Cortef® (hydrocortisone sodium succinate for injection, USP) 100 mg/2 mL (50 mg/mL) ACT-O-VIAL™ Single Dose Vial**, please reach out to your physician or pharmacy to request product under the emergency request process mentioned above.

Click For [Full Prescribing Information](#) including BOXED WARNING, if applicable.

**For all other Solu-Cortef® (hydrocortisone sodium succinate for injection, USP) presentations, please work with your pharmacies for availability.**

For additional questions, please reach out to the Supply Continuity Team between 7 a.m. and 6 p.m. (CT) at 1-844-646-4398 (select option 1 [Customer], then option 3 [Supply Continuity Team]). For medical inquiries, please contact Pfizer Medical Information at 1-800-438-1985 or [pfizermedinfo.com](https://pfizermedinfo.com).

Linna Wilkins  
Director, Cardiovascular & Steroids  
Pfizer Hospital U.S.